ArticleGene therapy2002
On the scientific and ethical issues of fetal somatic gene therapy.
Article in Gene therapy, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Prenatal and Postnatal Therapies for Down's Syndrome and Associated Developmental Anomalies and Degenerative Deficits: A Systematic Review of Guidelines and Trials.Frontiers in medicine · 2022Pooled it
- Prenatal therapies: a Points to Consider framework for responsible innovation.BMC medical genomics · 2025Review
- Prenatal gene editing for neurodevelopmental diseases: Ethical considerations.American journal of human genetics · 2025Review
- Therapeutic potential of combined viral transduction and CRISPR/Cas9 gene editing in treating neurodegenerative diseases.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2018Review
- Abortion decisions as inclusion and exclusion criteria in research involving pregnant women and fetuses.Journal of medical ethics · 2012Article
- Regulatory and ethical issues for phase I in utero gene transfer studies.Human gene therapy · 2011Article
- Targeting the central nervous system with herpes simplex virus / Sleeping Beauty hybrid amplicon vectors.Current gene therapy · 2011Review
- Minimal risk in research involving pregnant women and fetuses.The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics · 2011Article
- Factors determining the risk of inadvertent retroviral transduction of male germ cells after in utero gene transfer in sheep.Human gene therapy · 2009Article
- Gene therapy progress and prospects: fetal gene therapy--first proofs of concept--some adverse effects.Gene therapy · 2005Review
- Efficient engraftment of in utero transplanted mice with retrovirally transduced hematopoietic stem cells.Gene therapy · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fetal somatic gene therapy is often seen as an ethically particularly controversial field of gene therapy. This review outlines the hypothesis and scientific background of in utero gene therapy and addresses some of the frequently raised questions and concerns in relation to this still experimental, potentially preventive gene therapy approach. We discuss here the choice of vectors, of animal models and routes of administration to the fetus. We address the relation of fetal gene therapy to abortion, to post-implantation selection and postnatal gene therapy and the concerns of inadvertent germ-line modification. Our views on the specific risks of prenatal gene therapy and on the particular prerequisites that have to be met before human application can be considered are presented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.